• well as the trademark rights (TM) in Hong Kong, Australia, Indonesia, Malaysia, New Zealand and Singapore
• This transaction continues the successful acquisition of STADA's Nizoral Brands in several EMEA markets
• STADA EVP Emerging Markets Stephane Jacqmin: "We are very pleased about this important expansion step in the Asia-Pacific region. This asset acquisition further strengthens STADA's role as a partner of choice in consumer healthcare"

The pharmaceutical company STADA is expanding its Consumer Healthcare business in the Asia-Pacific region with the acquisition of Nizoral Cream from Janssen Pharmaceutica NV, a Johnson & Johnson company. The product with the active ingredient ketoconazole is indicated for the treatment of fungal skin infections. 

Under the terms of the agreement, STADA acquires the existing distribution and Nizoral Cream business in the markets Vietnam, Philippines and Thailand as well as the trademark rights (TM) in Hong Kong, Australia, Indonesia, Malaysia, New Zealand and Singapore. 

This transaction in an extension of a previous asset deal to the APAC region. In 2018, STADA successfully acquired the Nizoral brand in key EMEA markets.

STADA EVP Stephane Jacqmin Emerging Markets: “We are delighted to take this important step of expansion in the Asia-Pacific region. This partnership further strengthens STADA´s role as a partner of choice in consumer healthcare”.